COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Nicola Alexander HananiaScott H BunnerLindsay G S BengtsonAfisi S IsmailaMichael BogartPublished in: International journal of chronic obstructive pulmonary disease (2023)
In a real-world setting, patients on MITT who subsequently initiated FF/UMEC/VI in a single device had significant reductions in the rate of COPD exacerbations (moderate or severe). Switching to FF/UMEC/VI also resulted in improvements in some HCRU and cost outcomes. These data support the use of FF/UMEC/VI among patients at high risk of exacerbation to reduce future risk and improve outcomes.
Keyphrases
- chronic obstructive pulmonary disease
- healthcare
- lung function
- end stage renal disease
- cystic fibrosis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- palliative care
- type diabetes
- electronic health record
- big data
- clinical practice
- insulin resistance
- data analysis
- pain management
- affordable care act
- high intensity
- artificial intelligence
- patient reported outcomes
- adipose tissue
- skeletal muscle
- extracorporeal membrane oxygenation
- health information
- health insurance